Rabeprazole Sodium NDC 72189-142

NDC codes

FDA NDC Directory

Product NDC (as listed)72189-142Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72189-0142Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72189-142-30	72189014230	30 TABLET, DELAYED RELEASE in 1 BOTTLE (72189-142-30)Marketed from Oct 15, 2020
72189-142-90	72189014290	90 TABLET, DELAYED RELEASE in 1 BOTTLE (72189-142-90)Marketed from Oct 15, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rabeprazole Sodium
Generic name (nonproprietary): rabeprazole sodium
Active ingredients: Rabeprazole sodium — 20 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: DIRECT RX
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205761
Marketing start: Oct 15, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Proton Pump Inhibitors (Mechanism)
Identifiers: Product ID 72189-142_2be9206c-ed86-e301-e063-6294a90a43a8SPL ID 2be9206c-ed86-e301-e063-6294a90a43a8SPL set ID b1b7def0-834f-37f5-e053-2a95a90ade1fRxCUI 854868UNII 3L36P16U4R
Pharmacologic class: Proton Pump Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472189014230 followed by a unit qualifier and the quantity

Package 72189-0142-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 17, 2025.

Indications (excerpt from the label)

1.1 Healing of Erosive or Ulcerative GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenanc…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205761

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205761
Product	Strength	Form · route	Labeler	Product NDC
Rabeprazole Sodium	Rabeprazole sodium 20 mg/1	Tablet, Delayed releaseOral	Bryant Ranch Prepack	71335-1558
Rabeprazole Sodium	Rabeprazole sodium 20 mg/1	Tablet, Delayed releaseOral	Aurobindo Pharma Limited	65862-721
Rabeprazole Sodium	Rabeprazole sodium 20 mg/1	Tablet, Delayed releaseOral	Asclemed USA, Inc.	76420-107